AHR and myasthenia gravis: Using a translationally relevant model of ICH, we then showed that mice with selective AhR deficiency in MG have worse outcomes (neurological deficit and hematoma resolution) than the control mice, and systemic treatment of mice after ICH with a selective AhR agonist (ITE) improved the recovery in the control (loxP) mice, but not in mice with genetic deficiency of AhR, selectively in MG.